Details of the Drug Combination

General Information of Drug Combination (ID: DCEBYSW)

Drug Combination Name
Celecoxib Interferon Alfa-2b
Indication
Disease Entry Status REF
Malignant Neoplasm of Pancreas Metastatic to Peritoneal Surface Phase 1 [1]
Component Drugs Celecoxib   DM6LOQU Interferon Alfa-2b   DMWCQP4
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL is unavailable

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Celecoxib
Disease Entry ICD 11 Status REF
Dysmenorrhea GA34.3 Approved [2]
Lung cancer 2C25.0 Approved [2]
Osteoarthritis FA00-FA05 Approved [2]
Rheumatoid arthritis FA20 Approved [3]
Pain MG30-MG3Z Phase 3 [3]
Colon cancer 2B90.Z Investigative [2]
Familial adenomatous polyposis 2B90.Y Investigative [2]
Precancerous condition N.A. Investigative [2]
Celecoxib Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Prostaglandin G/H synthase 2 (COX-2) TTVKILB PGH2_HUMAN Inhibitor [5]
------------------------------------------------------------------------------------
Celecoxib Interacts with 5 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [6]
Sulfotransferase 1A1 (SULT1A1) DEYWLRK ST1A1_HUMAN Metabolism [7]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Metabolism [8]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Metabolism [9]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Metabolism [10]
------------------------------------------------------------------------------------
Indication(s) of Interferon Alfa-2b
Disease Entry ICD 11 Status REF
Melanoma 2C30 Approved [4]
Interferon Alfa-2b Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Interferon-alpha 2 (IFNA2) TTSIUJ9 IFNA2_HUMAN Modulator [12]
------------------------------------------------------------------------------------
Interferon Alfa-2b Interacts with 6 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
2'-5'-oligoadenylate synthase 1 (OAS1) OT8ZLOCY OAS1_HUMAN Increases Expression [11]
Interferon-induced, double-stranded RNA-activated protein kinase (EIF2AK2) OT8DXMS3 E2AK2_HUMAN Increases Expression [11]
Tyrosine-protein kinase JAK1 (JAK1) OT0X3D17 JAK1_HUMAN Increases Expression [11]
Signal transducer and activator of transcription 3 (STAT3) OTAAGKYZ STAT3_HUMAN Increases Phosphorylation [11]
Signal transducer and activator of transcription 1-alpha/beta (STAT1) OTLMBUZ6 STAT1_HUMAN Increases Expression [11]
Signal transducer and activator of transcription 2 (STAT2) OTO9G2RZ STAT2_HUMAN Increases Phosphorylation [11]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 DOT(s)

References

1 ClinicalTrials.gov (NCT02151448) alphaDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies. U.S. National Institutes of Health.
2 Celecoxib FDA Label
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2892).
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
5 Pfizer. Product Development Pipeline. March 31 2009.
6 Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor. J Pharmacol Exp Ther. 2000 May;293(2):453-9.
7 Sulfonation of 17beta-estradiol and inhibition of sulfotransferase activity by polychlorobiphenylols and celecoxib in channel catfish, Ictalurus punctatus. Aquat Toxicol. 2007 Mar 10;81(3):286-92.
8 Celecoxib is a substrate of CYP2D6: impact on celecoxib metabolism in individuals with CYP2C9*3 variants. Drug Metab Pharmacokinet. 2018 Oct;33(5):219-227.
9 Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies. Pharmacogenomics. 2009 Sep;10(9):1489-510.
10 Drug interactions in dentistry: the importance of knowing your CYPs. J Am Dent Assoc. 2004 Mar;135(3):298-311.
11 6-Hydroxy-3-O-methyl-kaempferol 6-O-glucopyranoside potentiates the anti-proliferative effect of interferon / by promoting activation of the JAK/STAT signaling by inhibiting SOCS3 in hepatocellular carcinoma cells. Toxicol Appl Pharmacol. 2017 Dec 1;336:31-39. doi: 10.1016/j.taap.2017.10.004. Epub 2017 Oct 12.
12 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.